Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Interventional × rrCLL × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 980 Neoplasms 844 Carcinoma, Non-Small-Cell Lung 831 Prostatic Neoplasms 519 Neoplasm Metastasis 497 Leukemia, Myeloid, Acute 486 Melanoma 449 Colorectal Neoplasms 440 Multiple Myeloma 434 Lung Neoplasms 413 Lymphoma 348 Pancreatic Neoplasms 347 Recurrence 346 Ovarian Neoplasms 338 Lymphoma, Non-Hodgkin 325 Leukemia 322 Leukemia, Lymphocytic, Chronic, B-Cell 300 Precursor Cell Lymphoblastic Leukemia-Lymphoma 269 Carcinoma, Renal Cell 254 Head and Neck Neoplasms 245 Brain Neoplasms 242 Carcinoma, Hepatocellular 231 Myelodysplastic Syndromes 229 Glioblastoma 227 Squamous Cell Carcinoma of Head and Neck 225 Lymphoma, Large B-Cell, Diffuse 224 Lymphoma, Follicular 216 Colonic Neoplasms 188 Stomach Neoplasms 180 Rectal Neoplasms 170

Interventions

pembrolizumab 1 dinaciclib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02684617 2021-03-01

KEYNOTE-155

Merck Sharp & Dohme LLC

Phase 1 Terminated

75 enrolled 17 charts

rrCLL

Data powered by HemOnc (CC BY 4.0) Colophon ⚡